Sumatriptan Tablet
Product Images NDC 50090-1129

6 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Sumatriptan (NDC 50090-1129). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label Image (Lbl500901129)

Label Image (Lbl500901129)
Sumatriptan 50 mg oral tablets packaging label from A-S Medication Solutions. The label states the product contains sumatriptan succinate USP, equivalent to 50 mg sumatriptan, with a total of 9 unit-dose tablets. Storage instructions specify to keep at 68 to 77 degrees Fahrenheit.*
FDA Label Image

Label Image (Lbl500901130)

Label Image (Lbl500901130)
Sumatriptan 100 mg oral tablets packaging label from A-S Medication Solutions. The label states each tablet contains 140 mg of Sumatriptan Succinate equivalent to 100 mg of Sumatriptan. The package contains 9 unit-dose tablets. Additional instructions to see the package insert for dosing information are included.*
FDA Label Image

Label Image (Lbl500902144)

Label Image (Lbl500902144)
Label for Sumatriptan 25 mg tablets, a human prescription drug by A-S Medication Solutions. The label states the active ingredient as sumatriptan succinate USP equivalent to 25 mg sumatriptan. It includes storage instructions to keep the product at 68 to 77 degrees Fahrenheit and specifies a package size of 9 unit-dose tablets.*
FDA Label Image

Figure 1. Estimated Probability Of Achieving Initial Headache Response Within 4 Hours Of Treatment In Pooled Trials 1, 2, And 3a (Sumatriptan Fig1)

Figure 1. Estimated Probability Of Achieving Initial Headache Response Within 4 Hours Of Treatment In Pooled Trials 1, 2, And 3a (Sumatriptan Fig1)
A line graph depicting the estimated probability of response over time in minutes from the initial dose for Sumatriptan oral tablets at strengths of 25 mg, 50 mg, and 100 mg, compared to placebo. The graph shows response increasing over 240 minutes, with higher doses generally showing higher probabilities of response.*
FDA Label Image

Figure 2. The Estimated Probability Of Patients Taking A Second Dose Of Sumatriptan Tablets Or Other Medication To Treat Migraine Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Trials 1, 2, And 3a (Sumatriptan Fig2)

Figure 2. The Estimated Probability Of Patients Taking A Second Dose Of Sumatriptan Tablets Or Other Medication To Treat Migraine Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Trials 1, 2, And 3a (Sumatriptan Fig2)
A line graph showing the estimated probability of remediation or rescue over time in hours from the initial dose of Sumatriptan oral tablets. Four curves represent placebo, 25 mg, 50 mg, and 100 mg doses, illustrating how probability changes within 24 hours after administration.*
FDA Label Image

Chemical Structure (Sumatriptan Str)

Chemical Structure (Sumatriptan Str)
Chemical structure of Sumatriptan Succinate, showing its molecular arrangement with indole ring, sulfonamide group, and succinate moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.